Numerous researches have shown that treatment with PD-1/PD-L1 inhibitors is more effective in cancers with more CD8 + T cells which may be used as predictive and therapeutic biomarkers for anti-PD-1 therapy [39, 40]. Here, PDCD1 is linked to cancer.